Speedel Group: Strings Attached? No Problem

Speedel Group sets itself apart from many in-licensing companies by offering partners a call-back option on development projects. This, plus its tight focus on renin inhibition and Big Pharma savvy management have allowed the group to build a pipeline. Critics say the model restricts Speedel's upside. But the success of its first project, Novartis' Phase III SPP100, and one of Europe's largest private financings of 2003 suggest the group has a strong chance of proving them wrong.